Prestige Consumer Healthcare (NYSE:PBH) Downgraded by StockNews.com to “Hold”

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

PBH has been the topic of several other reports. Jefferies Financial Group reaffirmed a “hold” rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research note on Monday. Finally, DA Davidson reiterated a “buy” rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Hold” and a consensus price target of $85.25.

Prestige Consumer Healthcare Stock Up 1.2 %

NYSE:PBH traded up $0.97 during trading hours on Tuesday, reaching $84.25. The company’s stock had a trading volume of 375,918 shares, compared to its average volume of 251,839. The stock has a 50 day moving average price of $77.27 and a two-hundred day moving average price of $72.19. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The company has a market capitalization of $4.16 billion, a P/E ratio of 20.50, a price-to-earnings-growth ratio of 2.37 and a beta of 0.49. Prestige Consumer Healthcare has a 12 month low of $57.95 and a 12 month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same period in the prior year, the business posted $1.07 EPS. The firm’s quarterly revenue was down .9% on a year-over-year basis. Equities analysts predict that Prestige Consumer Healthcare will post 4.44 EPS for the current fiscal year.

Insider Activity

In related news, SVP Mary Beth Fritz sold 9,885 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the transaction, the senior vice president now directly owns 18,835 shares in the company, valued at approximately $1,543,904.95. This trade represents a 34.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,810 shares of company stock valued at $3,187,300. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently made changes to their positions in PBH. Lombard Odier Asset Management USA Corp acquired a new stake in Prestige Consumer Healthcare in the second quarter valued at approximately $550,000. Sequoia Financial Advisors LLC grew its stake in Prestige Consumer Healthcare by 12.9% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock valued at $708,000 after acquiring an additional 1,120 shares during the period. Pinnacle Associates Ltd. increased its holdings in Prestige Consumer Healthcare by 60.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 24,630 shares of the company’s stock worth $1,776,000 after acquiring an additional 9,269 shares in the last quarter. Ariel Investments LLC increased its stake in shares of Prestige Consumer Healthcare by 10.7% during the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after purchasing an additional 274,212 shares in the last quarter. Finally, Boston Trust Walden Corp acquired a new position in shares of Prestige Consumer Healthcare during the 3rd quarter worth about $41,785,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.